FDA Approves Ruxience Biosimlar to Rituxan

The FDA approved rituximab-pvvr a rituximab biosimilar for use alone or in combination with chemotherapy for the treatment of adults with CD20-positive B-cell non-Hodgkin lymphoma NHL and chronic lymphocytic leukemia CLL as well as granulomatosis with pol [...]